Follicular thyroid carcinoma

Modern Pathology

Volumn 24, Issue , 2011, Pages S10-S18

  Sobrinho Simões, Manuel ^a,b,c   Eloy, Catarina ^a,c   Magalhães, João ^a,b,c   Lobo, Cláudia ^d   Amaro, Teresina ^d  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

Diagnosis; Follicular thyroid carcinoma; Molecular biomarkers; Prognosis

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOCYTIC THYROID FOLLICULAR CARCINOMA; POORLY DIFFERENTIATED CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADENOMA; ADENOMA, OXYPHILIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEOPLASM INVASIVENESS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953312456     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.133     Document Type: Article

References (73)

1. Sobrinho Simões M, Asa SL, Kroll TG, et al. Follicular carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds). WHO Classification of Tumors. Pathology and Genetics. Tumours of Endocrine Organs. IARC Press: Lyon, France, 2004. pp 67-76.
2. Rosai J, Carcangiu ML, DeLellis R. Tumors of the Thyroid Gland: Atlas of Tumor Pathology. Vol 5. 3rd series Armed Forces Institute of Pathology: Washington, DC, 1992. pp 343.
3. LiVolsi VA. Surgical Pathology of The Thyroid. WB Saunders: Philadelphia, PA, 1990.
4. LiVolsi VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. Thyroid 1994;4:233-236.
5. Alevizaki M, Papageorgiou G, Rentziou G, et al. Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental. Thyroid 2009;19:749-754.
6. Kakudo K, Bai Y, Katayama S, et al. Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute. Pathol Int 2009;59:359-367.
7. Rosai J, editor Rosai and Ackerman’s Surgical Pathology. Vol 1. 9th edn. Mosby: London, 2004, pp 1482.
8. Mete O, Asa SL. Definition and clinical significance of vascular invasion in thyroid carcinomas derived from follicular epithelium. Mod Pathol 2010;23(Supp 1):131A.
9. Maximo V, Sobrinho-Simoes M. Hurthle cell tumours of the thyroid. A review withemphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 2000;437:107-115.
10. Máximo V, Soares P, Sobrinho Simoes M. Mitochondria and cancer. Virchows Arch 2009;454:481-495.
11. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007;31:1256-1264.
12. Johannessen JV, Sobrinho-Simões M, Lindmo T, et al. The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid. Am J Clin Pathol 1982;77:20-25.
13. Castro P, Sansonetty F, Soares P, et al. Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern. Virchows Arch 2001;438:336-342.
14. Castro P, Eknaes M, Teixeira MR, et al. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol 2005;206: 305-311.
15. Sobrinho-Simões M, Preto A, Rocha AS, et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 2005;447:787-793.
16. Johannessen JV, Sobrinho-Simões M, Tangen KO, et al. A flow cytometric deoxyribonucleic acid analysis of papillary thyroid carcinoma. Lab Invest 1981;45: 336-341.
17. Soares P, dos Santos NR, Seruca R, et al. Benign and malignant thyroid lesions show instability at microsatellite loci. Eur J Cancer 1997;33:293-296.
18. Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective followup study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol 1986;10: 246-255.
19. van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 1992;112: 1130-1136.
20. Thompson LD, Wieneke JA, Paal E, et al. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001;91:505-524.
21. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318-2326.
22. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARg rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:213-220.
23. Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002;87:3947-3952.
24. Fonseca E, Soares P, Cardoso-Oliveira M, et al. Diagnostic criteria in well-differentiated thyroid carcinomas. Endocr Pathol 2006;17:109-117.
25. de Matos PS, Ferreira AP, de Oliveira FF, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005;47:391-401.
26. Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005;18: 48-57.
27. Papotti M, Rodriguez J, De Pompa R, et al. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 2005;18:541-546.
28. Cho Mar K, Eimoto T, Tateyama H, et al. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 2006;48: 286-294.
29. Cho Mar K, Eimoto T, Nagaya S, et al. Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid. Histopathology 2006;48:801-807.
30. Rigaud C, Bogomoletz WV. Apparent lack of usefulness of monoclonal antibody Ki-67 in thyroid tumour pathology. Relation to histological typing and classification. Pathol Res Pract 1991;187:198-200.
31. Soares P, Sobrinho-Simöes M. Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. Cancer 1994;73:2879-2881.
32. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474-1479.
33. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357-1360.
34. Sobrinho-Simões M, Máximo V, Rocha AS, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 2008;37:333-362.
35. Cheung CC, Ezzat S, Ramyar L, et al. Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 2000;85:878-882.
36. Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 2004;64: 2898-2903.
37. Giordano TJ. Genome-wide studies in thyroid neoplasia. Endocrinol Metab Clin North Am 2008;37:311-331.
38. Eszlinger M, Krohn K, Hauptmann S, et al. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab 2008;93:3286-3294.
39. Cerutti JM, Delcelo R, Amadei MJ, et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004;113:1234-1242.
40. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005-1010.
41. Pleasance ED, Stephens PJ, O’Meara S, et al. A smallcell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184-190.
42. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191-196.
43. Williams ED. Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 2003;8:181-183.
44. Hofman V, Lassalle S, Bonnetaud C, et al. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch 2009; 455:21-33.
45. Hapke MR, Dehner LP. The optically clear nucleus. A reliable sign of papillary carcinoma of the thyroid? Am J Surg Pathol 1979;3:31-38.
46. Castro P, Fonseca E, Magalhães J, et al. Follicular, papillary, and ‘hybrid’ carcinomas of the thyroid. Endocr Pathol 2002;13:313-320.
47. Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006;107:1255-1264.
48. Baloch ZW, LiVolsi VA. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol 2000;13:861-865.
49. Ivanova R, Soares P, Castro P, et al. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch 2002;440:418-424.
50. Carcangiu M, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985;55:805-828.
51. Rosai J, Zampi G, Carcangiu ML. Papillary carcinoma of the thyroid. A discussion of its several morphologic expressions, with particular emphasis on the follicular variant. Am J Surg Pathol 1983;7:809-817.
52. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202: 247-251.
53. Rocha AS, Soares P, Seruca R, et al. Abnormalities of E-cadherin/catenin complex in classical papillary thyroid carcinoma and its diffuse sclerosing variant. J Pathol 2001;194:358-366.
54. Soares P, Berx G, van Roy F, et al. E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer 1997;70:32-38.
55. Castro P, Soares P, Gusmão L, et al. H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid. Oncogene 2006;25:4620-4627.
56. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003;120:71-77.
57. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs non-encapsulated infiltrative) reveals distinct BRAF and RAS mutations patterns. Mod Pathol 2010;23(Supp 1):pp132A.
58. Roque L, Nunes VM, Ribeiro C, et al. Karyotypic characterization of papillary thyroid carcinomas. Cancer 2001;92:2529-2538.
59. Wreesmann VB, Ghossein RA, Hezel M, et al. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 2004;40:355-364.
60. Finn SP, Smyth P, Cahill S, et al. Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch 2007;450:249-260.
61. Celestino R, Magalhães J, Castro P, et al. A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. Histopathology 2009;55:482-487.
62. Widder S, Guggisberg K, Khalil M, et al. A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery 2008;144:80-85.
63. Piana S, Frasoldati A, Di Felice E, et al. Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the family rates from thyroid carcinoma. Am J Surg Pathol 2010;34:868-872.
64. Sobrinho-Simoes M, Albores-Saavedra J, Tallini G, et al. Poorly differentiated carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, (eds). WHO Classification of Tumors. Pathology and Genetics. Tumours of Endocrine Organs. IARC Press: Lyon, France, 2004. pp 73-76.
65. Sobrinho-Simões M, Magalhães J, Fonseca E, et al. Diagnostic pitfalls of thyroid pathology. Curr Diagnost Pathol 2005;11:52-59.
66. Sobrinho-Simoes M, Maximo V, Vieira de Castro I, et al. Hurthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol 2005;13:29-35.
67. Sobrinho-Simoes MA, Nesland JM, Holm R, et al. Hurthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct Pathol 1985;8:131-142.
68. Máximo V, Botelho T, Capela J, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid. Br J Cancer 2005;92:1892-1898.
69. Máximo V, Soares P, Lima J, et al. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology. A study with emphasis on Hürthle cell tumors. Am J Pathol 2002;160:1857-1865.
70. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated to papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 2005;446:589-595.
71. Tallini G, Hsueh A, Liu S, et al. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 1999;79:547-555.
72. Evans HL, Vassilopoulou-Sellin R. Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol 1998;22:1512-1520.
73. Couto JP, Prazeres H, Castro P, et al. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. J Clin Pathol 2009;62:414-421.